Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
-
Published:2022-12
Issue:6
Volume:7
Page:100629
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Di Lauro V.,
Barchiesi G.,
Martorana F.ORCID,
Zucchini G.,
Muratore M.,
Fontanella C.,
Arpino G.,
Del Mastro L.,
Giuliano M.,
Puglisi F.,
De Laurentiis M.
Subject
Cancer Research,Oncology
Reference72 articles.
1. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer;Burstein;N Engl J Med,2020
2. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future;Spring;Lancet,2020
3. Overall survival with ribociclib plus letrozole in advanced breast cancer;Hortobagyi;N Engl J Med,2022
4. Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer;Loibl;Breast,2022
5. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE);Johnston;J Clin Oncol,2020
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献